Taper Approach. The Deprescribing Guidelines for the Elderly project has developed an evidence-based guideline to support clinicians in safely reducing or stopping proton pump inhibitors, a class of drugs that reduce acid production in the stomach. The team has also developed a deprescribing algorithm to help clinicians decide when and how to reduce proton pump inhibitors safely and how to monitor effect. See links in the section below.
- Proton Pump Inhibitor evidence-based deprescribing guideline (published in Canadian Family Physician) [Bruyere Research Institute at deprescribing.org]
- Proton Pump Inhibitor deprescribing algorithm [Bruyere Research Institute at deprescribing.org]
- Whiteboard video on using the Proton Pump Inhibitor deprescribing algorithm [Bruyere Research Institute at deprescribing.org]
- Patient handout on Proton Pump Inhibitors [Bruyere Research Institute at deprescribing.org]
- Proton Pump Inhibitor (PPI) Patient Decision Aid [Bruyere Research Institute at deprescribing.org]
- A guide to deprescribing proton pump inhibitors [Primary Health Tasmania (Tasmania PHN)]
- Thompson W, Hogel M, Li Y, Thavorn K, O’Donnell D, McCarthy L, Dolovich L Black C, Farrell B. Effect of a proton pump inhibitor deprescribing guideline on drug usage and costs in long-term care. JAMDA, 2016, in press, doi.org/10.1016/j.jamda.2016.04.020.
- Boghossian TA, Rashid FJ, Welch V, Rojas-Fernandez C, Moayyedi P, Pottie K, Walsh K, Pizzola L, Thompson W, Farrell B. Deprescribing versus continuation of chronic proton pump inhibitor use in adults (protocol). Cochrane Database Syst Rev, 2015; Issue 11, article number CD011969.